Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
51 hedge funds and large institutions have $51.1M invested in Astria Therapeutics in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 6 closing their positions.
81% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $644K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 50 → 51 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $51.5M → $51.1M (-$411K)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
1.5% less ownership
Funds ownership: 44.73% → 43.23% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.44M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$917K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$631K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$445K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$345K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$1.29M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$883K |
| 3 |
Renaissance Technologies
New York
|
-$669K |
| 4 |
Two Sigma Investments
New York
|
-$299K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$241K |
ATXS Hedge Fund Activity: Q3 2020 in Review
51 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2020, worth a combined $51.1M — down 0.8% from $51.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATXS positions and 6 closed out — a net gain of 1 holder — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $2.44M. The largest seller was Blackstone Inc, exiting entirely with an estimated $1.29M sold.
- 51 institutional investors held Astria Therapeutics (ATXS) as of Q3 2020, up from 50 in Q2 2020.
- Funds reported $51.1M of Astria Therapeutics stock for Q3 2020, down 0.8% quarter-over-quarter.
- 7 funds opened new Astria Therapeutics positions in Q3 2020 and 6 closed out, a net change of +1 holder.
- The largest Astria Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $2.44M added.
- The largest Astria Therapeutics seller in Q3 2020 was Blackstone Inc, an estimated $1.29M sold.
Based on aggregated 13F filings for Q3 2020.